Development and validation of a nomogram model for predicting immune-mediated hepatitis in cancer patients treated with immune checkpoint inhibitors
BioScience Trends · 2025
DOI: 10.5582/bst.2024.01351 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift BioScience Trends, 2025. Verfasst von Qianjie Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Nomograms, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have been widely used in various types of cancer, but they have also led to a significant number of adverse events, including ICI-induced immune-mediated hepatitis (IMH). This study aimed to explore the risk factors for IMH in patients treated with ICIs and to develop and validate a new nomogram model to predict the risk of IMH. Detailed information was collected between January 1, 2020, and December 31, 2023. Univariate logistic regression analysis was used to assess the impact of each clinical variable on the occurrence of IMH, followed by stepwise multivariate logistic regression analysis to determine independent risk factors for IMH. A nomogram model was constructed based on the results of the multivariate analysis. The performance of the nomogram model was evaluated via the area under the receiver operating characteristic curve (AUC), calibration curves, decision curve analysis (DCA), and clinical impact curve (CIC) analysis. A total of 216 (8.82%) patients developed IMH. According to stepwise multivariate logistic analysis, hepatic metastasis, the TNM stage, the WBC count, LYM, ALT, TBIL, ALB, GLB, and ADA were identified as risk factors for IMH. The AUC for the nomogram model was 0.817 in the training set and 0.737 in the validation set. The calibration curves, DCA results, and CIC results indicated that the nomogram model had good predictive accuracy and clinical utility. The nomogram model is intuitive and straightforward, making it highly suitable for rapid assessment of the risk of IMH in patients receiving ICI therapy in clinical practice. Implementing this model enables early adoption of preventive and therapeutic strategies, ultimately reducing the likelihood of immune-related adverse events (IRAEs), and especially IMH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing, China.
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Health Statistics, School of Public Health, Chongqing Medical University, Chongqing, China.
- Hepatobiliary Pancreatic Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
Zitieren
APA
Xu, Q., Li, X., Yuan, Y., Hu, Z., Zhang, W., Wang, Y., Shen, A., & Lei, H. (2025). Development and validation of a nomogram model for predicting immune-mediated hepatitis in cancer patients treated with immune checkpoint inhibitors. BioScience Trends. https://doi.org/10.5582/bst.2024.01351
Vancouver
Xu Q, Li X, Yuan Y, Hu Z, Zhang W, Wang Y, et al. Development and validation of a nomogram model for predicting immune-mediated hepatitis in cancer patients treated with immune checkpoint inhibitors. BioScience Trends. 2025. doi:10.5582/bst.2024.01351
BibTeX
@article{Xu2025,
author = {Xu, Qianjie and Li, Xiaosheng and Yuan, Yuliang and Hu, Zuhai and Zhang, Wei and Wang, Ying and Shen, Ai and Lei, Haike},
title = {Development and validation of a nomogram model for predicting immune-mediated hepatitis in cancer patients treated with immune checkpoint inhibitors},
journal = {BioScience Trends},
year = {2025},
doi = {10.5582/bst.2024.01351}
}
EUVIMED